



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/759,576	01/16/2004	Jian-Bing Fan	067234-0104	8734

7590 08/07/2006

David A. Gray
MCDERMOTT WILL & EMERY LLP
4370 LaJolla Village Drive Suite 700
San Diego, CA 92122

EXAMINER

FORMAN, BETTY J

ART UNIT	PAPER NUMBER
----------	--------------

1634

DATE MAILED: 08/07/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/759,576

Applicant(s)

FAN ET AL.

Examiner

BJ Forman

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-36 is/are pending in the application.
4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-36 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 16 January 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____.
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____.
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: ____.

DETAILED ACTION

Priority

1. This application is a divisional of co-pending application 09/785,514.

Claims 1-36 are currently pending and under prosecution.

Claim Objections

2. Claim 13 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 13, which depends from itself, does not further limit itself.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Art Unit: 1634

4. Claims 1-2, 5, 7-8, 10-13, 28-29, 32, 34-36 are rejected under 35 U.S.C. 102(b) as being anticipated by Walt et al (WO 98/40726, published 17 September 1998).

Regarding Claim 1, Walt et al disclose an array composition comprising a substrate having discrete sites and a population of microspheres comprising a first and second subpopulation, the microspheres of the subpopulations comprising a plurality of different target analytes e.g. antibodies and antigens (see Fig. 3 and Example 1, pages 24-25) wherein the microspheres are distributed on the surface (page 7, lines 5-15 and Fig. 5 and 7).

Regarding Claim 2, Walt et al disclose the array wherein each microsphere further comprise an optical signature (page 10, lines 4-5).

Regarding Claim 5, Walt et al disclose the array wherein the analytes are nucleic acids i.e. probe and target hybridized to the target (page 16, line 28-page 17, line 10 and Table V).

Regarding Claim 7, Walt et al disclose the array wherein the target analytes are proteins (e.g. antibodies and antigens, Example 2, page 27, lines 8-33).

Regarding Claim 8, Walt et al disclose the array wherein the substrate is a fiber optic (Abstract).

Regarding Claim 10, Walt et al disclose the array wherein the discrete sites are wells (page 20, lines 27-33 and Fig. 5).

Regarding Claim 11, Walt et al disclose the array wherein the microspheres are randomly distributed (page 7, lines 10-15).

Regarding Claim 12, Walt et al disclose the array wherein the analytes of the different subpopulations are from different target source (e.g. rabbit, goat, mouse, Example 2, page 27, lines 9-16).

Regarding Claim 13, Walt et al disclose the array wherein the different sources are different patients (e.g. rabbit, goat, mouse, Example 2, page 27, lines 9-16). It is noted that the claim does not define the patient as human. Hence, the analytes from the animals listed above are encompassed by the claimed patient.

Art Unit: 1634

Regarding Claim 28, Walt et al disclose a composition comprising a population of microspheres comprising a first and second subpopulation, the microspheres of the subpopulations comprising a plurality of different target analytes e.g. antibodies and antigens (see Fig. 3 and Example 1, pages 24-25) wherein the microspheres are distributed on the surface (page 7, lines 5-15 and Fig. 5 and 7).

Regarding Claim 29, Walt et al disclose the composition wherein each microspheres further comprise an optical signature (page 10, lines 4-5).

Regarding Claim 32, Walt et al disclose the composition wherein the analytes are nucleic acids i.e. probe and target hybridized to the target (page 16, line 28-page 17, line 10 and Table V).

Regarding Claim 34, Walt et al disclose the array wherein the target analytes are proteins (e.g. antibodies and antigens, Example 2, page 27, lines 8-33).

Regarding Claim 35, Walt et al disclose the array wherein the analytes of the different subpopulations are from different target source (e.g. rabbit, goat, mouse, Example 2, page 27, lines 9-16).

Regarding Claim 36, Walt et al disclose the array wherein the different sources are different patients (e.g. rabbit, goat, mouse, Example 2, page 27, lines 9-16). It is noted that the claim does not define the patient as human. Hence, the analytes from the animals listed above are encompassed by the claimed patient.

5. Claims 1-2, 5-29, 32-36 are rejected under 35 U.S.C. 102(e) as being anticipated by Walt et al (U.S. Patent No. 6,327,410, filed 11 Sept 1998).

Regarding Claim 1, Walt et al disclose an array composition comprising a substrate having discrete sites and a population of microspheres comprising a first and second

Art Unit: 1634

subpopulation, the microspheres of the subpopulations comprising a plurality of different target analytes e.g. antibodies and antigens (Fig. 3 and Column 27, lines 30-60) wherein the microspheres are distributed on the surface (Column 4, lines 35-50).

Regarding Claim 2, Walt et al disclose the array wherein each microsphere further comprise an optical signature (Column 4, lines 48-50).

Regarding Claim 5, Walt et al disclose the array wherein the analytes are nucleic acids i.e. probe and target hybridized to the target (Column 11, lines 25-35).

Regarding Claim 6, Walt et al disclose the array wherein the nucleic acids are genomic DNA (Column 11, lines 25-35).

Regarding Claim 7, Walt et al disclose the array wherein the target analytes are proteins (e.g. antibodies and antigens, Column 27, lines 30-60).

Regarding Claim 8, Walt et al disclose the array wherein the substrate is a fiber optic (Column 5, lines 24-31).

Regarding Claim 9, Walt et al disclose the array wherein the substrate is plastic (Column 5, lines 37-40).

Regarding Claim 10, Walt et al disclose the array wherein the discrete sites are wells (Column 5, lines 61-67).

Regarding Claim 11, Walt et al disclose the array wherein the microspheres are randomly distributed (Column 4, lines 46-48).

Regarding Claim 12, Walt et al disclose the array wherein the analytes of the different subpopulations are from different target source (e.g. rabbit, goat, mouse, Column 27, lines 30-60).

Regarding Claim 13, Walt et al disclose the array wherein the different sources are different patients (e.g. rabbit, goat, mouse, Column 27, lines 30-60). It is noted that the claim does not define the patient as human. Hence, the analytes from the animals listed above are encompassed by the claimed patient.

Art Unit: 1634

Regarding Claim 14, Walt et al disclose a composition comprising a substrate having discrete sites (i.e. sub-bundles, Column 18, lines 59-65), wherein each discrete site has a plurality of different target analytes (e.g. 5000 different bioactive agents, Column 18, line 65-Column 19, line 2) the bioactive agents covalently attached to the microspheres within the discrete sites (Column 11, lines 63-65).

Regarding Claim 15, Walt et al disclose the composition wherein the analytes are covalently attached to the substrate i.e. the analytes are covalently attached to the microspheres which are covalently attached to the substrate (Column 6, lines 48-50 and Column 11, lines 63-65).

Regarding Claim 16, Walt et al disclose the composition wherein a plurality of different analytes are covalently attached to microspheres and the microspheres are distributed in the discrete sites i.e. the analytes are covalently attached to the microspheres which randomly distributed and covalently attached to the substrate (Column 4, lines 42-55; Column 6, lines 48-50; and Column 11, lines 63-65).

Regarding Claim 17, Walt et al disclose the array wherein the analytes are nucleic acids i.e. probe and target hybridized to the target (Column 11, lines 25-35).

Regarding Claim 18, Walt et al disclose the array wherein the nucleic acids are genomic DNA (Column 11, lines 25-35).

Regarding Claim 19, Walt et al disclose the array wherein the target analytes are proteins (e.g. antibodies and antigens, Column 27, lines 30-60).

Regarding Claim 20, Walt et al disclose the array wherein the substrate is a fiber optic (Column 5, lines 24-31).

Regarding Claim 21, Walt et al disclose the array wherein the substrate is plastic (Column 5, lines 37-40).

Regarding Claim 22, Walt et al disclose the array wherein the discrete sites are wells (Column 5, lines 61-67).

Art Unit: 1634

Regarding Claim 23, Walt et al disclose the array wherein the analytes of the different subpopulations are from different target source (e.g. rabbit, goat, mouse, Column 27, lines 30-60).

Regarding Claim 24, Walt et al disclose the array wherein the different sources are different patients (e.g. rabbit, goat, mouse, Column 27, lines 30-60). It is noted that the claim does not define the patient as human. Hence, the analytes from the animals listed above are encompassed by the claimed patient.

Regarding Claim 25, Walt et al disclose the composition wherein the discrete sites are at a density of about 100,000 to 10,000,000 per cm^2 (Column 5, lines 4-31).

Regarding Claim 26, Walt et al disclose the composition wherein the discrete sites are at a density of about 10,000,000 to 1,000,000,000 per cm^2 (Column 5, lines 5-31).

Regarding Claim 27, Walt et al disclose the composition wherein the discrete sites are at a density of about 10,000 to 100,000 per cm^2 (Column 5, lines 4-31).

Regarding Claim 28, Walt et al disclose a composition comprising a population of microspheres comprising a first and second subpopulation, the microspheres of the subpopulations comprising a plurality of different target analytes e.g. antibodies and antigens (Fig. 3 and Column 27, lines 30-60) wherein the microspheres are distributed on the surface (Column 4, lines 35-50).

Regarding Claim 29, Walt et al disclose the array wherein each microsphere further comprise an optical signature (Column 4, lines 48-50).

Regarding Claim 32, Walt et al disclose the array wherein the analytes are nucleic acids i.e. probe and target hybridized to the target (Column 11, lines 25-35).

Regarding Claim 33, Walt et al disclose the array wherein the nucleic acids are genomic DNA (Column 11, lines 25-35).

Regarding Claim 34, Walt et al disclose the array wherein the target analytes are proteins (e.g. antibodies and antigens, Column 27, lines 30-60).

Art Unit: 1634

Regarding Claim 35, Walt et al disclose the array wherein the analytes of the different subpopulations are from different target source (e.g. rabbit, goat, mouse, Column 27, lines 30-60).

Regarding Claim 36, Walt et al disclose the array wherein the different sources are different patients (e.g. rabbit, goat, mouse, Column 27, lines 30-60). It is noted that the claim does not define the patient as human. Hence, the analytes from the animals listed above are encompassed by the claimed patient.

6. Claims 1-36 are rejected under 35 U.S.C. 102(e) as being anticipated by Chee et al (U.S. Patent No. 6,355,431, filed 3 March 2000 and claiming priority to 20 May 1999).

The applied reference has a common inventor and assignee with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

Regarding Claim 1, Chee et al disclose an array composition comprising a substrate having discrete sites and a population of microspheres containing first and second subpopulations wherein each microsphere comprises a plurality of different target analytes (i.e. capture probe and modified primer) wherein the microspheres are distributed on the surface. (e.g. amplifier probes, Column 34, line 32-Column 36, line 14).

Regarding Claim 2, Chee et al disclose the array composition wherein the microspheres further comprising an optical signature (Column 38, lines 54-56).

Art Unit: 1634

Regarding Claims 3-4, Chee et al disclose the array composition wherein the microspheres further comprising a nucleic acid identifier binding ligand (Column 44, lines 8-60).

Regarding Claims 5-6, Chee et al disclose the array wherein the target analytes are genomic DNA (Column 8, lines 62-65).

Regarding Claim 7, Chee et al disclose the array wherein the analytes are proteins (e.g. IBL-DBL pairs, Column 44, lines 27-60).

Regarding Claim 8, Chee et al disclose the array composition wherein the substrate is a fiber optic (Column 38, lines 40-42).

Regarding Claim 9, Chee et al disclose the array composition wherein the substrate is plastic (Column 38, lines 31-33).

Regarding Claim 10, Chee et al disclose the array composition wherein the discrete sites are wells (Column 38, lines 31-33).

Regarding Claim 11, Chee et al disclose the array composition wherein the microspheres are randomly distributed on the surface (Column 38, lines 52-55).

Regarding Claim 12, Chee et al disclose the array composition wherein the first and second subpopulations comprise analytes from first and second sources e.g. multiplex detection of different polymorphisms (Column 56, line 63-Column 57, line 19).

Regarding Claim 13, Chee et al disclose the array composition wherein the different sources are patients (Column 56, lines 23-32).

Regarding Claim 14, Chee et al disclose a composition comprising a substrate comprising discrete sites wherein each site comprising a plurality of different covalently attached target analytes (i.e. analytes are covalently attached to the microspheres, Column 43, lines 56-57).

Art Unit: 1634

Regarding Claim 15, Chee et al disclose the composition wherein the analytes are covalently attached to the substrate (i.e. analytes are covalently attached to the microspheres, Column 43, lines 56-57, which are covalently attached to the wells, Column 42, lines 29-31).

Regarding Claim 16, Chee et al disclose the composition wherein the analytes are covalently attached to the microspheres (Column 43, lines 56-57) and the microsphere are distributed in discrete sites (Column 38, lines 52-55).

Regarding Claims 17-18, Chee et al disclose the array wherein the target analytes are genomic DNA (Column 8, lines 62-65).

Regarding Claim 19, Chee et al disclose the array wherein the analytes are proteins (e.g. IBL-DBL pairs, Column 44, lines 27-60).

Regarding Claim 20, Chee et al disclose the array composition wherein the substrate is a fiber optic (Column 38, lines 40-42).

Regarding Claim 21, Chee et al disclose the array composition wherein the substrate is plastic (Column 38, lines 31-33).

Regarding Claim 22, Chee et al disclose the array composition wherein the discrete sites are wells (Column 38, lines 31-33).

Regarding Claim 23, Chee et al disclose the array composition wherein the first and second subpopulations comprise analytes from first and second sources e.g. multiplex detection of different polymorphisms (Column 56, line 63-Column 57, line 19).

Regarding Claim 24, Chee et al disclose the array composition wherein the different sources are patients (Column 56, lines 23-32).

Regarding Claim 25, Chee et al disclose the composition wherein the discrete sites are at a density of about 100,000 to 10,000,000 per cm^2 (Column 39, line 52-Column 40, line 27).

Regarding Claim 26, Chee et al disclose the composition wherein the discrete sites are at a density of about 10,000,000 to 1,000,000,000 per cm^2 (Column 39, line 52-Column 40, line 27).

Art Unit: 1634

Regarding Claim 27, Chee et al disclose the composition wherein the discrete sites are at a density of about 10,000 to 100,000 per cm² (Column 39, line 52-Column 40, line 27).

Regarding Claim 28, Chee et al disclose an array composition comprising a substrate having discrete sites and a population of microspheres containing first and second subpopulations wherein each microsphere comprises a plurality of different target analytes (e.g. capture probe and modified primer) wherein the microspheres are distributed on the surface. (e.g. amplifier probes, Column 34, line 32-Column 36, line 14).

Regarding Claim 29, Chee et al disclose the array composition wherein the microspheres further comprising an optical signature (Column 38, lines 54-56).

Regarding Claims 30-31, Chee et al disclose the array composition wherein the microspheres further comprising a nucleic acid identifier binding ligand (Column 44, lines 8-60).

Regarding Claims 32-33, Chee et al disclose the array wherein the target analytes are genomic DNA (Column 8, lines 62-65).

Regarding Claim 34, Chee et al disclose the array wherein the analytes are proteins (e.g. IBL-DBL pairs, Column 44, lines 27-60).

Regarding Claim 35, Chee et al disclose the array composition wherein the first and second subpopulations comprise analytes from first and second sources e.g. multiplex detection of different polymorphisms (Column 56, line 63-Column 57, line 19).

Regarding Claim 36, Chee et al disclose the array composition wherein the different sources are patients (Column 56, lines 23-32).

Claim Rejections - 35 USC § 103

7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1634

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

8. Claims 3, 4, 30 and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Walt et al (U.S. Patent No. 6,327,410, filed 11 Sept 1998) in view of Dower et al (U.S. Patent No. 5,770,358, issued 23 June 1998).

Regarding Claims 3, 4, 30, 31, Walt et al disclose an array composition comprising a substrate having discrete sites and a population of microspheres comprising a first and second subpopulation, the microspheres of the subpopulations comprising a plurality of different target analytes e.g. antibodies and antigens (Fig. 3 and Column 27, lines 30-60) wherein the microspheres are distributed on the surface (Column 4, lines 35-50).

Walt et al do not teach the array/composition further comprising a nucleic acid identifier binding ligand. However, nucleic acid identifier binding ligands (oligo-tags) were well known and routinely practiced in the art at the time the claimed invention was made as taught by Dower et al (Abstract). Dower et al teach the oligo-tags are used to encode a library of compounds on microspheres and provide a dramatic improvement in library compound production and identification (Column 8, lines 40-47). It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to modify the microspheres of Walt et al by attaching the oligo-tags that encode the bioactive agent. One of ordinary skill in the art would have been motivated to do so for the expected benefit of facilitating production and screening of the bioactive agent as taught by Dower et al (Column 4, line 66-Column 5, line 6 and Column 8, lines 40-47).

Double Patenting

9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or

Art Unit: 1634

improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

10. Claims 1-36 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 21-35 of U.S. Patent No. 6,355,431. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a composition of microsphere populations on a substrate. The claim sets merely differ in that the patent claims define the microspheres as having capture probes while the instant claims define the capture probes in the independent claims as analytes and in dependent claims as proteins or nucleic acids. However, the genus of capture probes recited in the patent claims is a relatively small groups such that nucleic acids and proteins would have been obvious to one of ordinary skill. Therefore, the instantly claimed compositions would have been an obvious application of the patent composition.

11. Claims 1-36 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 6,544,732. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a composition of microsphere populations on a substrate.

Art Unit: 1634

The claim sets merely differ in that the patent claims define the microspheres as nanocrystals. However, the instantly claimed microspheres are generic to the patent nanocrystal microspheres. Furthermore, the instant claims define the microspheres as having two different analytes. However, the '732 specification defines use of the patent composition during which the patent microspheres comprise two analytes (Column 3, lines 21-33). Therefore, the patent specification defines the patent composition as comprising the second analyte as instantly claimed. Therefore, the claim sets are not patentably distinct.

12. Claims 1-36 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-30 of U.S. Patent No. 6,429,027. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a composition of microsphere populations on a substrate. The claim sets merely differ in the arrangement of limitations within the claim sets and further that the instant claims define the microspheres as having two different analytes. However, the '027 specification defines use of the patent composition during which the patent microspheres comprise two analytes (Column 5, lines 49-55). Therefore, the patent specification defines the patent composition as comprising the second analyte as instantly claimed. Therefore, the claim sets are not patentably distinct.

13. Claims 1-5, 28-31 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 14 of U.S. Patent No. 6,620,584. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a composition of microsphere populations on a substrate.

Art Unit: 1634

The claim sets merely differ in the terminology used to define the molecules of the microspheres. For example, the instant claims define the microspheres as having two analytes e.g. nucleic acid and nucleic acid identifier while the patent microspheres are defined as having a primer and decoding sequence. However, the primer and decoding sequences are defined in the patent specification as nucleic acids (Fig. 6-7). Therefore, the patent specification defines the patent composition as comprising the second analyte as instantly claimed. Therefore, the claim sets are not patentably distinct.

14. Claims 1-36 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 38, 40-47, 52-54, 58-62 of copending Application No. 09/189,543. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a composition of microsphere populations on a substrate. The claim sets merely differ in the arrangement of limitations within the claim sets.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

15. No claim is allowed.

16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BJ Forman whose telephone number is (571) 272-0741. The examiner can normally be reached on 6:00 TO 3:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.


Art Unit: 1634

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.



BJ Foramen, Ph.D.
Primary Examiner
Art Unit: 1634
August 3, 2006